Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial comparing Loncastuximab Tesirine to Idelalisib in relapsed or refractory follicular lymphoma was terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Idelalisib (idelalisib)
• Loncastuximab tesirine (loncastuximab tesirine)

Snippet

Sponsor: ADC Therapeutics S.A. | Conditions: Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2023-10-23